This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Labetalol Hydrochloride

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20221018

Version

5

Spl Product Data Elements

Labetalol Hydrochloride Labetalol Hydrochloride LABETALOL HYDROCHLORIDE LABETALOL ALUMINUM OXIDE D&C YELLOW NO. 10 FERRIC OXIDE RED FERRIC OXIDE YELLOW HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE POLYETHYLENE GLYCOL, UNSPECIFIED SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN TALC TITANIUM DIOXIDE YELLOW BICONVEX 7;98 Labetalol Hydrochloride Labetalol Hydrochloride LABETALOL HYDROCHLORIDE LABETALOL HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE POLYETHYLENE GLYCOL, UNSPECIFIED SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN TITANIUM DIOXIDE OFF-WHITE BICONVEX 7;99 Labetalol Hydrochloride Labetalol Hydrochloride LABETALOL HYDROCHLORIDE LABETALOL FD&C BLUE NO. 1--ALUMINUM LAKE FERRIC OXIDE YELLOW HYPROMELLOSES LACTOSE MONOHYDRATE MAGNESIUM STEARATE POLYETHYLENE GLYCOL, UNSPECIFIED SODIUM STARCH GLYCOLATE TYPE A POTATO STARCH, CORN TALC TITANIUM DIOXIDE LIGHT GREEN BICONVEX 800

Application Number

ANDA207743

Brand Name

Labetalol Hydrochloride

Generic Name

Labetalol Hydrochloride

Product Ndc

70771-1163

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1163-3 Labetalol hydrochloride tablets, 100 mg Rx only 30 tablets NDC 70771-1164-3 Labetalol hydrochloride tablets, 200 mg Rx only 30 tablets NDC 70771-1165-3 Labetalol hydrochloride tablets, 300 mg Rx only 30 tablets Labetalol hydrochloride tablets Labetalol hydrochloride tablets Labetalol hydrochloride tablets

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.